Andrew P. Han

The report also mentions a US investor class action lawsuit that alleges Illumina and Grail officials oversold Galleri's potential.

The decision comes just weeks after Grail officials touted the decision as a potential positive catalyst for the firm as it prepares to be divested by Illumina.

One near-term indicator of Grail's prospects could come if the firm submits data on the first year of its NHS study to the UK government.

Whether Illumina will sell Grail to another firm or pursue a capital markets transaction such as an initial public offering is yet to be determined.

The program will provide funding and expertise to clinics in low-income countries to run methylation array-based assays to classify central nervous system tumors in children.

SomaLogic Cofounder and former CEO Larry Gold and Chief Technology Officer Jason Cleveland have filed a class action suit, accusing the board of breach of fiduciary duty.

The sequencing instrument maker said it plans to finalize terms for a sale or IPO by the end of the second quarter of 2024.

While AMP asked members to register their opposition officially, one official said "there probably will be a lawsuit."

A comparison for 144 solid tumor samples showed a "high degree of alignment" with FoundationOne CDx and better calling of CNAs than Illumina's TSO 500.

The so-called "five-base" assay, which includes methylation calls thanks to PacBio's Revio instrument, will be evaluated as a frontline test for critically ill newborns.